As the only TAVI product with motorized retrievable delivery system in the Latin American market, VitaFlow Liberty^® combines the advantages of VitaFlow^® ’s valve design with groundbreaking improvements to the delivery system.

The rapid development of VitaFlow^® series products in the field of interventional valve therapy in Latin America will further help CardiFlow gain more recognition in overseas potential markets.

Shanghai, China - MicroPort^® CardioFlow Medtech Corporation ("MicroPort^® CardioFlow ", stock code: 02160.HK) recently announced that its self-developed new generation Transcatheter Aortic Valve Implantation (hereinafter referred to as "TAVI") product, The VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (hereinafter referred to as "VitaFlow Liberty^®"), and Angleguide^® Tip-preshaped Super Stiff Guidewire (hereinafter referred to as "Angelguide^®"), have been granted marketing approval by Colombia's National Food and Drug Regulatory Agency ("INVIMA").

As the Iterative product of VitaFlow^® Transcatheter Aortic Valve and Delivery System ("VitaFlow^®"), VitaFlow Liberty^® inherits the advantages of VitaFlow^® transcatheter aortic valve system in valve design. In addition, its groundbreaking breakthrough upgraded delivery system, adding the retrievable function combined with the world’s first double reinforced spiral capsule on the basis of the electric handle, achieving flexibility, directionlessness of delivery system and valve segment’s 360°range of motion.

In addition to VitaFlow Liberty^®, Angelguide^®，developed by MicroPort^® CardioFlow, has also been approved for marketing in Colombia, where its high guidewire support and smooth delivery make it highly supportive, minimizing the likelihood of myocardial and vascular injury while improving release precision.

The approval of VitaFlow Liberty^® in Colombia marks the product's once again entry into the Latin American market following its approval in Argentina as well as another milestone on the road to internationalization for MicroPort^® CardioFlow, and provides impetus for MicroPort^® CardioFlow to enter more overseas potential markets. In the future, MicroPort^® CardioFlow will actively develop innovative technologies, launch more internationally competitive products, and promote TAVI products "Made in China" to more countries and regions, so as to bring high-quality, universal total solutions for structural heart disease to more patients around the world.